Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has issued an update.
SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register a new 2ml specification of its Composite Potassium Hydrogen Phosphate Injection, classified as a type 3 chemical drug and deemed to have passed consistency evaluation. The injection, used to correct hypophosphatemia and provide parenteral nutrition when enteral feeding is not feasible in adult and pediatric patients, strengthens the group’s injectable nutrition portfolio and reflects ongoing product development that may enhance its competitive position in China’s hospital pharmaceutical sector.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a Hong Kong-listed pharmaceutical group engaged in the development and production of injectable drugs, with a focus on hospital and clinical nutrition applications in the China market.
YTD Price Performance: 6.01%
Average Trading Volume: 5,631,778
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.85B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.